

November 21, 2008

Interprotein Corporation

Adoption of Interprotein's VEGF project in Super Special Consortia
for supporting the development of cutting-edge medical care

Interprotein Corporation (Interprotein) inform that "Project of Early Clinical Development for Anti Cancer Medicine and Device", the Leader, Dr. Hiroyasu Esumi, Director of National Cancer Center Hospital East, which we are joining, was adopted in Super Special Consortia for supporting the development of cutting-edge medical care.

Interprotein's 'Orally available small molecule VEGF (vascular endothelial growth factor) inhibitor project' is one the subjects of the coalition and its clinical trials are planned to be conducted in the collaborative work with the Dr. Yasuhiro Fujiwara's clinical development team in National Cancer Center Hospital and a global pharmaceutical company under Dr. Fujiwara's supervision.

Anti-VEGF antibody drug has been clinically used and its efficacy to prolong survival periods of patients with solid tumors has been well established, though it is not orally available but injection use only.

Interprotein succeeded in obtaining the information on the binding mode of VEGF and its receptor based on X-ray crystallographic data of the VEGF/VEGF-receptor complex, and then generated small molecule inhibitors using *in silico* Drug Design methods. We now have Lead compounds and are conducting the Lead Optimization step in order to develop orally available small molecule inhibitors. We would like to conduct pre-clinical studies of the candidate compound and its clinical trials as soon as possible in the Special Zone.

Regarding detailed information on Super Special Consortia for supporting the development of cutting-edge medical care and "Project of Early Clinical Development for Anti Cancer Medicine and Device", please access to home page of Cabinet Office

<http://www.cao.go.jp> <http://www8.cao.go.jp/cstp/project/tokku/index.html>

Over

3-9-7, Toyosaki Kita-ku, Osaka city, 531-0072

Interprotein Corporation

CEO & President Masato Hosoda

Contact: Shozo Kususita, Director, Administration Division Phone: +81-6-6374-5303